Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

• Published in: Journal of the American Academy of Dermatology Vol. 52; no. 3; pp. 425 - 433
• Main Authors: Leonardi, Craig L., Papp, Kim A., Gordon, Kenneth B., Menter, Alan, Feldman, Steven R., Caro, Ivor, Walicke, Patricia A., Compton, Peter G., Gottlieb, Alice B.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.03.2005; Elsevier
• Subjects: Adult; Aged; Antibodies, Monoclonal - therapeutic use; Biological and medical sciences; CD11 Antigens; Dermatologic Agents - therapeutic use; Dermatology; Double-Blind Method; Female; Humans; Immunologic Factors - therapeutic use; Male; Medical sciences; Middle Aged; Psoriasis - drug therapy; Psoriasis. Parapsoriasis. Lichen; UVB; PASI; sPGA; LFA-1; PPD; ITT; PGA; IVRS; PASI-90; PASI-50; SC; BSA; HAHA; PASI-75; PUVA; Phase III trial; Human; Immunomodulator; Skin disease; Chemotherapy; Chronic; Randomization; Treatment; Psoriasis; Dermatology; Monoclonal antibody; Efalizumab

Efalizumab inhibits multiple T-cell–mediated processes. To evaluate 12- and 24-week efalizumab therapy for psoriasis. In this phase III, randomized, double-blind trial, 498 patients received subcutaneous 1 or 2 mg/kg/wk efalizumab or placebo for 12 weeks. Efalizumab-treated patients who achieved <...